The Medicines Co (MDCO)

51.84
NASDAQ : Health Care
Prev Close 51.84
Day Low/High 0.00 / 0.00
52 Wk Low/High 29.48 / 54.01
Avg Volume 1.32M
Exchange NASDAQ
Shares Outstanding 70.79M
Market Cap 3.70B
EPS -5.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.

Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.

Ardelyx, Acorda Therapeutics and Medicines Co. were among the premarket biotech movers on Wednesday.

Insiders Seeing Green With MDCO At New 52-Week High

Insiders Seeing Green With MDCO At New 52-Week High

In trading on Friday, shares of Medicines Co touched a new 52-week high of $45.31/share. That's a 64.76% rise, or $17.81 per share from the 52-week low of $27.50 set back on 02/11/2016.

Premarket Biotech Movers: Portola, Esperion, Medicines

Premarket Biotech Movers: Portola, Esperion, Medicines

Portola Pharmaceuticals, Esperion Therapeutics and Medicines were among the biotech stock movers in premarket trading on Friday.

The Medicines Company To Present Results From ORION-1 Phase 2 Study Of Inclisiran At The American College Of Cardiology's 66th Annual Scientific Session

The Medicines Company To Present Results From ORION-1 Phase 2 Study Of Inclisiran At The American College Of Cardiology's 66th Annual Scientific Session

The Medicines Company (Nasdaq: MDCO) today announced that full safety and efficacy data from the ORION-1 Phase 2 study of inclisiran, with six- to nine-month follow-up for all patients in the study, will be presented at the...

The Medicines Company Announces Positive Top-Line Results From Day 180 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of Inclisiran (formerly, PCSK9si)

The Medicines Company Announces Positive Top-Line Results From Day 180 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of Inclisiran (formerly, PCSK9si)

The Medicines Company (Nasdaq:MDCO) today announced positive top-line results from the interim analysis with Day 180 follow-up for all 501 patients enrolled in the ongoing ORION-1 Phase 2 study of inclisiran, its...

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

The Medicines Company, Alder also see share boosts on favorable implications. Jim Cramer weighs in on the implications for Amgen investors.

The Medicines Company To Present At J. P. Morgan Healthcare Conference

The Medicines Company To Present At J. P. Morgan Healthcare Conference

The Medicines Company (Nasdaq: MDCO) today announced that its Chief Executive Officer, Clive Meanwell, M.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies -- including Medtronic and Medicines -- have been scooping up shares of their own stock lately.

The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)

The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)

The Medicines Company (Nasdaq:MDCO) and Alnylam Pharmaceuticals, Inc.

Http://www.themedicinescompany.com/

Http://www.themedicinescompany.com/

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a leading biopharmaceutical development and cardiovascular product company, today...

The Medicines Company To Host Conference Call And Webcast To Review Data From Ongoing ORION-1 Phase 2 Study Of PCSK9si

The Medicines Company To Host Conference Call And Webcast To Review Data From Ongoing ORION-1 Phase 2 Study Of PCSK9si

The Medicines Company (NASDAQ: MDCO) will host a conference call and webcast on Tuesday, November 15, 2016, at 3:00 p.

The Medicines Company Discontinues Development Of MDCO-216, Its Investigational Cholesterol Efflux Promoter

The Medicines Company Discontinues Development Of MDCO-216, Its Investigational Cholesterol Efflux Promoter

The Medicines Company (NASDAQ:MDCO) announced today the immediate discontinuation of the clinical development program for MDCO-216, its investigational cholesterol efflux promoter.

The Medicines Company Reports Third-Quarter 2016 Financial Results

The Medicines Company Reports Third-Quarter 2016 Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its financial results for the third quarter ended September 30, 2016.

The Medicines Company Announces Positive Top-Line Results From Day 90 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of PCSK9si

The Medicines Company Announces Positive Top-Line Results From Day 90 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of PCSK9si

The Medicines Company (NASDAQ:MDCO) today announced top-line results from the interim analysis with Day 90 follow-up for all 501 patients enrolled in the ongoing ORION-1 study of PCSK9si, its investigational first-in-class...

The Medicines Company To Announce Third Quarter Financial Results On October 26, 2016

The Medicines Company To Announce Third Quarter Financial Results On October 26, 2016

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for October 26, 2016 at 8:30 a.

The Medicines Company's Infectious Disease Portfolio Featured In 16 Presentations At IDWeek 2016

The Medicines Company's Infectious Disease Portfolio Featured In 16 Presentations At IDWeek 2016

The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products and product candidates will be featured in 16 presentations at IDWeek 2016, to be held October 26-30,...

The Medicines Company To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY® 2016 Annual Meeting And The ISAP 25th Annual Meeting

The Medicines Company To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY® 2016 Annual Meeting And The ISAP 25th Annual Meeting

The Medicines Company (NASDAQ:MDCO) today announced that five abstracts with data from its investigational anesthetic MDCO-700 (formerly, ABP-700) development program will be presented at ANESTHESIOLOGY® 2016,...

Why Medicines Co. (MDCO) Stock is Falling Today

Why Medicines Co. (MDCO) Stock is Falling Today

Medicines Co. (MDCO) stock is under pressure today because its drug development partner Alnylam Pharmaceuticals (ALNY) ended testing on one of its gene-silencing treatments.

The Medicines Company Provides Progress Update On Ongoing ORION-1 Study Of PCSK9si

The Medicines Company Provides Progress Update On Ongoing ORION-1 Study Of PCSK9si

The Medicines Company (NASDAQ:MDCO) today provided a progress update on the ongoing ORION-1 study of PCSK9si, its investigational first-in-class PCSK9 synthesis inhibitor.

Notable Wednesday Option Activity: MDCO, PEIX, BEAT

Notable Wednesday Option Activity: MDCO, PEIX, BEAT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Medicines Co , where a total volume of 4,663 contracts has been traded thus far today, a contract volume which is representative of approximately 466,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 57.9% of MDCO's average daily trading volume over the past month, of 805,825 shares.

The Medicines Company Awarded Up To $132 Million To Develop Portfolio Of New Antibiotics Targeting Drug-Resistant Infections Under Strategic Partnership With BARDA

The Medicines Company Awarded Up To $132 Million To Develop Portfolio Of New Antibiotics Targeting Drug-Resistant Infections Under Strategic Partnership With BARDA

The Medicines Company (NASDAQ:MDCO) today announced that it has entered into a new strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant...

The Medicines Company Provides Update On Dyslipidemia Programs

The Medicines Company Provides Update On Dyslipidemia Programs

The Medicines Company (NASDAQ:MDCO) today provided an update on its clinical dyslipidemia research programs for MDCO-216 (which contains APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor).

The Medicines Company Reports Second-Quarter 2016 Business And Financial Results

The Medicines Company Reports Second-Quarter 2016 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the second quarter ended June 30, 2016.

The Medicines Company To Announce Second Quarter Financial Results On July 27, 2016

The Medicines Company To Announce Second Quarter Financial Results On July 27, 2016

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for July 27, 2016 at 8:30 a.

Federal Circuit Rules For The Medicines Company In Angiomax® (bivalirudin) Patent Litigation

Federal Circuit Rules For The Medicines Company In Angiomax® (bivalirudin) Patent Litigation

The Medicines Company announced that the U.S.

Barbarian At The Gate: Medicines (MDCO)

Barbarian At The Gate: Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Medicines (MDCO) Flagged As Strong On High Volume

Medicines (MDCO) Flagged As Strong On High Volume

Trade-Ideas LLC identified Medicines (MDCO) as a strong on high relative volume candidate

The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®

The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®

The Medicines Company (NASDAQ:MDCO) today announced that its investigational antibiotic, CARBAVANCE ® (meropenem-vaborbactam), met both FDA and EMA pre-specified primary endpoints in the Phase 3 TANGO 1 clinical trial...